Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 194, Issue 2, Pages 256-260Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/504691
Keywords
-
Categories
Funding
- NIAID NIH HHS [R56 AI63503-01A1, AI063382, R01 AI48031, R01 AI19990, K08 AI060641] Funding Source: Medline
- NIDCR NIH HHS [DE017088] Funding Source: Medline
- PHS HHS [R01 A1054928] Funding Source: Medline
Ask authors/readers for more resources
We have shown that vaccination with the recombinant N terminus of Als1p (rAls1p-N) protects mice against disseminated and oropharyngeal candidiasis. We now report that vaccination of mice with a related candidate, rA1s3p-N, induces a broader antibody response than rA1s1p-N and a similar cell-mediated immune response. The rA1s3p-N vaccine was equally as effective as rA1s1p-N against disseminated candidiasis but was more effective than rAls1p-N against oropharyngeal or vaginal candidiasis. Antibody titers did not correlate with protection against disseminated candidiasis, but delayed-type hypersensitivity did. The rA1s3p-N vaccine is a promising new vaccine candidate for further exploration to prevent systemic and mucosal candidal infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available